# Oxytocin sensitivity and postpartum hemorrhage: testing genetic and epigenetic biomarkers for improving maternal morbidity

> **NIH NIH R01** · UNIVERSITY OF ARIZONA · 2024 · $288,649

## Abstract

Postpartum hemorrhage is a complication of childbirth that affects 3-8% of births in the United States, each
year this represents a minimum of 120,000 births. Postpartum hemorrhage is also a primary cause of maternal
mortality worldwide. Rates of severe postpartum hemorrhage and hemorrhage requiring invasive treatments or
blood transfusions are on the rise, particularly for labors that are induced. Severe hemorrhage is also more
common among women of color, contributing to disparities in maternal health. Oxytocin is a naturally occurring
hormone as well as a medication used to stimulate labor, prevent or treat postpartum hemorrhage. Oxytocin
binds available oxytocin receptors in uterine muscle, stimulating contraction. While oxytocin is the first-line
hemorrhage treatment, people who have been given oxytocin to stimulate contractions during labor are more
likely to have a less effective uterine contraction response to oxytocin administered postpartum, leading to
more bleeding and the need for other medical treatments or procedures. Currently, 4 of 10 people who
hemorrhaged, did so despite not having been identified as high risk by current clinical prediction tools. This
inaccuracy and the rising rates of hemorrhage indicate that more research is needed to help identify possible
risks for this potentially life-threatening complication. Because people with ineffective labor contractions or a
personal/family history (of hemorrhage) are more likely to have postpartum hemorrhage, the role of innate
oxytocin function/ sensitivity is the primary focus of this investigation. As such, our lab has been researching
biomarkers that can help identify people at risk for hemorrhage by testing how genetic and epigenetic variation
of the oxytocin receptor gene is associated with oxytocin response and hemorrhage. In this proposal, we use a
biosocial framework to test the central hypothesis that maternal variation in the oxytocin receptor gene can be
useful for predicting pharmacologic oxytocin needs and hemorrhage. First, we will examine DNA methylation
(epigenetic differences) from blood samples using banked data as well as prospectively collected non-invasive
salivary samples in association with oxytocin needs in labor and postpartum hemorrhage. Social determinants
of health will be examined in association with DNA methylation differences; evaluating the role of adverse
environments in shaping the oxytocin receptor epigenotype. Furthermore, we will test how DNA methylation
affects gene expression and the oxytocin receptor availability in uterine tissues. Second, we will examine
genetic variants of the oxytocin receptor gene in association with the clinical endpoints with the aforementioned
specimens and test pharmacologic response by measuring contractility of uterine muscle specimens. Given
that clinicians have no method of predicting how well oxytocin will work in the emergency of postpartum
hemorrhage, we aim to develop a clinically useful biomarker measuring...

## Key facts

- **NIH application ID:** 11128085
- **Project number:** 3R01HD111125-02S1
- **Recipient organization:** UNIVERSITY OF ARIZONA
- **Principal Investigator:** Elise N Erickson
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $288,649
- **Award type:** 3
- **Project period:** 2023-08-01 → 2028-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11128085

## Citation

> US National Institutes of Health, RePORTER application 11128085, Oxytocin sensitivity and postpartum hemorrhage: testing genetic and epigenetic biomarkers for improving maternal morbidity (3R01HD111125-02S1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/11128085. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*